Stratifying Non-Small Cell Lung Cancer Subtypes via Tumor-Associated Fibroblast Angiogenic Profiles

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Cell Death & Disease https://doi.org/10.1038/s41419-026-08677-2
Dr. Natalia Díaz-Valdivia et al.

Points

Lung adenocarcinoma and squamous cell carcinoma respond differently to anti-angiogenic drugs due to variations in their fibroblast-rich tumor microenvironments.
Fibroblasts in lung adenocarcinoma actively promote robust blood vessel formation through a cooperative synergy between vascular endothelial growth factor A and TIMP-1.
A novel function was discovered for TIMP-1 in driving endothelial cell hyperbranching, which explains why lung adenocarcinoma metastasizes earlier than squamous cell carcinoma.
Higher tobacco exposure in squamous cell carcinoma causes molecular alterations in associated fibroblasts, resulting in inefficient vessel formation and an acidic, hypoxic environment.
Tailoring precision oncology treatments requires targeting the stroma-derived SMAD3/TIMP-1 pathways in lung adenocarcinoma while addressing severe tissue hypoxia and acidosis in squamous cell carcinoma.

Summary

This study evaluated the mechanistic variations underlying disparate responses to anti-angiogenic therapies between the two major histologic subtypes of non-small cell lung cancer (NSCLC): lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). While LUAD is the most common subtype and responds favorably to anti-angiogenic interventions, LUSC is the second most common subtype and exhibits historical treatment resistance. By integrating transcriptomics (bulk and single-cell RNA-seq), angiogenesis arrays, and functional assays, the research sought to determine how tumor-associated fibroblasts (TAFs) shape histotype-specific microenvironments.

The analysis revealed that LUAD exhibits highly active, functional angiogenesis characterized by increased oxygen levels and reduced cell necrosis. The LUAD-TAF secretome is specifically primed for vascular growth through SMAD3-dependent overproduction of vascular endothelial growth factor A (VEGF-A) and tissue inhibitor of metalloproteinases-1 (TIMP-1). Mechanistically, the study uncovered a novel role for TIMP-1 in driving endothelial cell hyperbranching over basal VEGF signaling, facilitating early access to the blood vessel network. Consequently, these findings explain why LUAD tumors demonstrate an increased propensity for early metastatic dissemination compared to LUSC.

Conversely, LUSC-TAFs display inefficient blood vessel formation, culminating in a highly acidic, hypoxic microenvironment with increased cell death. Despite upregulating hypoxia-inducible factor 1-alpha (HIF-1α) and a hypoxia-associated transcriptional signature, LUSC-TAFs exhibit diminished angiogenic capabilities due to lower SMAD3 expression and a compensatory increase in SMAD2. These findings suggest that uniform therapeutic strategies are inadequate for NSCLC. Precision oncology protocols should utilize stroma-derived biomarkers like TIMP-1 to stratify patients, targeting specific SMAD3/TIMP-1 pathways in LUAD and microenvironmental stressors like hypoxia or acidosis in LUSC.

Link to the article: https://www.nature.com/articles/s41419-026-08677-2

References

Díaz-Valdivia, N., Duch, P., Ikemori, R., Parker, A. L., Arshakyan, M., Llorente, A., Bernardo, A., Rodríguez-Rojas, J., Carrasco, J. L., Park, D., Sahai, E., Fillat, C., Juan, M., Nadal, E., Reguart, N., Radisky, D. C., Casanovas, O., & Alcaraz, J. (2026). Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer. Cell Death & Disease, 17(1), 431. https://doi.org/10.1038/s41419-026-08677-2